Cancer immunotherapy: Car T Cell Technology

A type of treatment in which a patient’s T cells (a type of immune cell) are altered in the laboratory so they will bind to cancer cells and destroy them. Blood from a vein in the patient’s arm flows through a tube to an apheresis machine (not shown), which eliminates the white blood cells, including the T cells, and directs the rest of the blood back to the patient. Then, the gene for a special receptor named a chimeric antigen receptor (CAR) is introduced into the T cells in the laboratory. Millions of the CAR T cells are developed in the laboratory and then given to the patient by infusion. The CAR T cells are able to bind to an antigen on the cancer cells and destroy them.

  • CAR-T cell therapy in acute lymphoblastic leukaemia
  • CAR-T cells therapy in chronic lymphocytic leukaemia
  • CAR-T cell in multiple myeloma

Related Conference of Cancer immunotherapy: Car T Cell Technology

March 18-19, 2024

20th International Conference on Cancer Research

Zurich, Switzerland
April 24-25, 2024

33rd Neonatology and Primary Care Congress

Paris, France
July 25-26, 2024

20th World Summit on Blockchain Technology

Amsterdam, Netherlands

Cancer immunotherapy: Car T Cell Technology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in